Scholarlink

<p><i>Streptococcus pneumoniae</i> (<i>S. pneumoniae</i>) remains a predominant cause of high morbidity and mortality in childhood and the elderly, despite the widespread pneumococcal conjugate vaccines (PCVs) vaccination through the world. The critical role of capsule in the pathogenicity of <i>S. pneumoniae</i> makes it an attractive drug target for alternative strategies to combat antibiotic-resistant and non-vaccine serotype infections. Here, we identified the natural compound molecule stevioside as an effective capsule inhibitor that reduces the biosynthesis of capsular polysaccharide through interfering with pyruvate metabolism and subsequent disruption of bacterial NAD + /NADH redox balance and energy generation. In vitro, the compound significantly sensitized streptococci to stress attacks and the killing of antibacterial peptides (AMPs). Meanwhile, capsule-mediated resistance to complement deposition, epithelial adherence and phagocytosis were all remarkably attenuated by stevioside. In vivo, stevioside treatment systematically protected mice from lethal streptococcal pneumoniae, as evident by an increased survival rate, alleviated pathological damage and inflammation level. Overall, the study provides stevioside as a promising lead compound for the further development of chemical capsule inhibitors aimed at curbing <i>S. pneumoniae</i> infections, and reveals a novel strategy for the discovery of <i>S. pneumoniae</i> capsule inhibitors based on pyruvate metabolism pathways.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stevioside curbs Streptococcus pneumoniae infection via inhibiting capsule biosynthesis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月9日

查看全文
  • Sanwei Gu,
  • Jian Zhang,
  • Xiaoye Fan,
  • Huacan Liu,
  • Huaizhi Yang,
  • Ying Ding,
  • Xuming Deng,
  • Lei Song,
  • Yanhong Deng,
  • Tingting Wang

摘要

Streptococcus pneumoniae (S. pneumoniae) remains a predominant cause of high morbidity and mortality in childhood and the elderly, despite the widespread pneumococcal conjugate vaccines (PCVs) vaccination through the world. The critical role of capsule in the pathogenicity of S. pneumoniae makes it an attractive drug target for alternative strategies to combat antibiotic-resistant and non-vaccine serotype infections. Here, we identified the natural compound molecule stevioside as an effective capsule inhibitor that reduces the biosynthesis of capsular polysaccharide through interfering with pyruvate metabolism and subsequent disruption of bacterial NAD + /NADH redox balance and energy generation. In vitro, the compound significantly sensitized streptococci to stress attacks and the killing of antibacterial peptides (AMPs). Meanwhile, capsule-mediated resistance to complement deposition, epithelial adherence and phagocytosis were all remarkably attenuated by stevioside. In vivo, stevioside treatment systematically protected mice from lethal streptococcal pneumoniae, as evident by an increased survival rate, alleviated pathological damage and inflammation level. Overall, the study provides stevioside as a promising lead compound for the further development of chemical capsule inhibitors aimed at curbing S. pneumoniae infections, and reveals a novel strategy for the discovery of S. pneumoniae capsule inhibitors based on pyruvate metabolism pathways.